ODI Pharma (ODI) Q4 25/26 earnings summary

Executive summary

• Achieved significant progress in commercial positioning, volume growth, and profitability, especially in Poland, with net sales rising to SEK 32.9 million from SEK 3.1 million year-over-year and profit after financial items improving to SEK 2.0 million from a loss of SEK 5.9 million.

• Four consecutive quarters of positive EBITDA and three consecutive quarters of positive net income signal sustained operational improvement.

• Ended the year debt-free after repaying the remaining EUR 150,000 working capital loan, strengthening the balance sheet.

• Added a new commission-based contract in Switzerland, contributing positively to net income.

Financial highlights

• Full-year net sales: SEK 32,915,945 (up from SEK 3,133,879 year-over-year).

• Profit after financial items: SEK 1,987,683 (compared to a loss of SEK 5,929,115 year-over-year).

• Q4 net sales: SEK 3,197,373 (up from SEK 6,461 in Q4 last year, but down sequentially from Q3 due to order timing).

• Q4 profit after financial items: SEK 153,040 (compared to a loss of SEK 1,660,970 in Q4 last year).

• Result per share for the year: SEK 0.11 (up from SEK -0.35 year-over-year).

Outlook and guidance

• Focus remains on consolidating and strengthening the position in Poland, with continued monitoring of regulatory and commercial developments in other European markets such as France.

• European medical cannabis market expected to grow in volume, though pricing pressure and regulatory changes will remain key factors.